Midfoot Solutions

Coming – August 27

11 Million Americans. $1B Market. 1 Solution.

Date and Time

August 27

–

12:00 PM ET / 9:00 AM PT

Details will be shared with confirmed attendees

About this Event

More than 11 million Americans over the age of 50 are affected by debilitating midfoot osteoarthritis. The condition causes chronic, often severe pain that significantly impairs mobility and limits everyday activities such as walking, climbing stairs, exercising, and even standing for extended periods.

Despite being the second largest segment of the foot and ankle market, current solutions are both invasive and relatively ineffective with little to no innovation over the years.

Innovative Midfoot Solutions (IMS) was founded specifically to address this gap. The company is developing sterile, single use, surgical kits for ease of physician use and reduced procedural time for midfoot osteoarthritis and progressive collapsing foot deformity. IMS’s proprietary, minimally invasive OrthoFuse™ and Precise™ Wedge platforms are designed to simplify midfoot procedures, improve surgical consistency, and enhance patient outcomes while being well positioned for rapid adoption in the rapidly growing Ambulatory Surgical Center (ASC) market.

The company estimates its initial target opportunity exceeds $1 billion globally, with additional expansion opportunities across other orthopedic indications using the same core technologies.

Join our 30-minute executive briefing with IMS President & CEO, Christopher E. Banas. Supported by established FDA 510(k) regulatory pathway, existing reimbursement, a growing patent portfolio, IMS is pursuing one of the largest underserved opportunities in orthopedic medicine.

Sign Up Today

SHARE THIS EVENT

This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts and referenced statistics, contained in this presentation, including statements regarding future company strategy, operations, financial position, revenues, projected costs, plans and objectives of management, will be forward-looking statements.

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.